rs150634297
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM1PM2
The NM_000258.3(MYL3):c.235G>A(p.Val79Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000644 in 1,614,160 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_000258.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYL3 | NM_000258.3 | c.235G>A | p.Val79Ile | missense_variant | Exon 3 of 7 | ENST00000292327.6 | NP_000249.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152168Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000278 AC: 7AN: 251470Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135916
GnomAD4 exome AF: 0.0000698 AC: 102AN: 1461874Hom.: 0 Cov.: 33 AF XY: 0.0000633 AC XY: 46AN XY: 727236
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152286Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74472
ClinVar
Submissions by phenotype
Cardiomyopathy Uncertain:2
This missense variant replaces valine with isoleucine at codon 79 of the MYL3 protein. Computational prediction tools indicate that this variant has a neutral impact on protein structure and function. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in one individual affected with a mild form of late-onset hypertrophic cardiomyopathy (PMID: 22957257). However, three carrier individuals from this family had electrocardiogram and/or echocardiographic abnormalities that did not fulfill diagnostic criteria for hypertrophic cardiomyopathy. In addition, five carrier individuals from this family showed an unaffected phenotype. This variant has been identified in 7/251470 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
- -
Hypertrophic cardiomyopathy Uncertain:2
This missense variant replaces valine with isoleucine at codon 79 of the MYL3 protein. Computational prediction tools indicate that this variant has a neutral impact on protein structure and function. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in one individual affected with a mild form of late-onset hypertrophic cardiomyopathy (PMID: 22957257). However, three carrier individuals from this family had electrocardiogram and/or echocardiographic abnormalities that did not fulfill diagnostic criteria for hypertrophic cardiomyopathy. In addition, five carrier individuals from this family showed an unaffected phenotype. This variant has been identified in 7/251470 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
This sequence change replaces valine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 79 of the MYL3 protein (p.Val79Ile). This variant is present in population databases (rs150634297, gnomAD 0.005%). This missense change has been observed in individual(s) with hypertrophic cardiomyopathy (PMID: 22957257). ClinVar contains an entry for this variant (Variation ID: 161329). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Primary familial hypertrophic cardiomyopathy Pathogenic:1
- -
not specified Uncertain:1
Variant summary: MYL3 c.235G>A (p.Val79Ile) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 2.8e-05 in 251470 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.235G>A has been reported in the literature as segregating with disease in at least one family, in which one heterozygous individual was diagnosed with asymptomatic hypertrophic cardiomyopathy (HCM) and 3 additional heterozygotes displayed borderline HCM; unaffected heterozygous carriers in the family were under the age of 30, suggesting this variant may cause late-onset and clinically silent disease (Andersen_2012). Therefore, this report does not provide unequivocal conclusions about association of the variant with Hypertrophic Cardiomyopathy. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Five ClinVar submitters (evaluation after 2014) have cited the variant, and all laboratories classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. -
Hypertrophic cardiomyopathy 8 Uncertain:1
- -
Cardiovascular phenotype Uncertain:1
The p.V79I variant (also known as c.235G>A), located in coding exon 3 of the MYL3 gene, results from a G to A substitution at nucleotide position 235. The valine at codon 79 is replaced by isoleucine, an amino acid with highly similar properties. This variant was detected in an asymptomatic individual with hypertrophic cardiomyopathy (HCM), as well as in three family members with borderline HCM findings and in six unaffected carrier family members, including some who were children at the time of evaluation (Andersen PS et al. Biochem Res Int, 2012 Apr;2012:685108). This variant has also been reported as a secondary finding in exome cohorts with limited clinical details provided (Lawrence L et al. Genet Med, 2014 Oct;16:741-50; Olfson E et al. PLoS One, 2015 Sep;10:e0135193). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at